Joshua C. Horan

The Practical Synthesis of a Novel and Highly Potent Analogue of Bryostatin

Paul A. Wender, Jeremy L. Baryza, Chad Bennett et al. · Journal of the American Chemical Society · 2002 · 154 citations

Macrocycle 1, Pharmaceutical Chemistry, Medicinal Chemistry +17

The Clinically-tested S1P Receptor Agonists, FTY720 and BAF312, Demonstrate Subtype-Specific Bradycardia (S1P1) and Hypertension (S1P3) in Rat

Ryan M. Fryer, Akalushi Muthukumarana, Paul C. Harrison et al. · PLoS ONE · 2012 · 78 citations · Full text

Hypertension, Cardiovascular Pharmacology, Modest Hypertension +16

Function Oriented Synthesis: The Design, Synthesis, PKC Binding and Translocation Activity of a New Bryostatin Analog

Paul A. Wender, Jeremy L. Baryza, Stacey E. Brenner et al. · Current Drug Discovery Technologies · 2004 · 51 citations

NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations

Alexander Drilon, Joshua C. Horan, Anupong Tangpeerachaikul et al. · Cancer Discovery · 2022 · 47 citations · Full text

Inspirations from nature. New reactions, new therapeutic leads, and new drug delivery systems

Paul A. Wender, Jeremy L. Baryza, Stacey E. Brenner et al. · Pure and Applied Chemistry · 2003 · 44 citations · Full text

Pharmaceutical Science, Lead Identification, Chemistry +19